US · MASS
908 Devices Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Boston, MA 02210
- Website
- 908devices.com
Price · as of 2024-12-31
$6.81
Market cap 249.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $20.23 | +197.06% |
| Intrinsic Value(DCF) | $1.10 | -83.85% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $17.16 | |||
| 2020 | $54.29 | $417.80 | $30.87 | $13.66 | $0.00 |
| 2021 | $18.58 | $477.02 | $76.19 | $3.71 | $0.00 |
| 2022 | $8.02 | $32.11 | $4.35 | $0.40 | $0.00 |
| 2023 | $6.86 | $24.89 | $2.80 | $0.00 | $0.00 |
| 2024 | $2.76 | $20.23 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates 908 Devices Inc.'s (MASS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $20.23
- Current price
- $6.81
- AI upside
- +197.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.10
-83.85% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MASS | 908 Devices Inc. | $6.81 | 249.73M | +197% | -84% | — | — | -1.30 | 0.82 | 1.58 | -0.71 | -1.49 | 1.36 | 50.18% | -128.65% | -121.09% | -51.56% | -197.59% | -39.84% | 0.06 | — | 4.10 | 3.27 | 0.85 | 8761.00% | 1872.00% | 1382.00% | -32.80% | -1.20 | -79.76% | 0.00% | 0.00% | 0.00% | -0.40 | -1.01 | 0.52 | -1.50 |
| ACRS | Aclaris Therapeutics, Inc… | $2.87 | 310.95M | +859% | -54% | — | +777% | -5.76 | 3.63 | 47.81 | -3.46 | — | 3.63 | 73.28% | -975.91% | -829.58% | -50.20% | 2416.55% | -34.10% | 0.00 | — | 5.28 | 5.28 | 0.31 | -6901.00% | -5819.00% | 13383.00% | -12.62% | -1.64 | 1494.19% | 0.00% | 0.00% | 0.00% | -2.92 | -4.72 | 28.46 | -5.14 |
| CAPR | Capricor Therapeutics, In… | $27.93 | 1.28B | -15% | -76% | — | -88% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| CERS | Cerus Corporation | $2.56 | 491.74M | +1,048% | -13% | — | — | -13.30 | 4.96 | 1.55 | -29.56 | — | 5.08 | 55.21% | -7.89% | -11.60% | -38.53% | -18.17% | -10.52% | 1.75 | -1.60 | 2.39 | 1.73 | -7.76 | -4762.00% | 1529.00% | -11784.00% | 3.06% | 0.18 | 10.88% | 0.00% | 0.00% | 2.34% | -20.83 | 34.77 | 1.64 | -5.07 |
| CVRX | CVRx, Inc. | $8.16 | 214.7M | +209% | -60% | — | — | -4.02 | 5.45 | 3.78 | -3.70 | — | 5.45 | 85.33% | -90.49% | -94.10% | -96.59% | -342.22% | -44.76% | 1.29 | -8.80 | 7.63 | 6.49 | 0.49 | -2302.00% | 1045.00% | 60.00% | -19.01% | -3.02 | -272.03% | 0.00% | 0.00% | 0.00% | -3.70 | -4.65 | 3.35 | -5.99 |
| NNOX | Nano-X Imaging Ltd. | $2.37 | 151.12M | +990% | +2% | — | — | -6.62 | 1.87 | 31.38 | -6.41 | — | 2.97 | -94.03% | -502.93% | -474.31% | -27.83% | -46.04% | -24.97% | 0.04 | — | 5.63 | 5.37 | 0.71 | -1574.00% | 1391.00% | -1813.00% | -11.12% | -2.62 | -32.15% | 0.00% | 0.00% | 0.00% | -5.08 | -7.32 | 25.55 | 7.21 |
| NPCE | NeuroPace, Inc. | $14.58 | 485.63M | +102% | +40% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| QTRX | Quanterix Corporation | $6.55 | 305.96M | +237% | -22% | -45% | — | -7.37 | 0.86 | 2.10 | -0.73 | -45.26 | 0.87 | 59.89% | -38.85% | -28.45% | -11.33% | -70.92% | -9.23% | 0.11 | — | 8.66 | 7.65 | 0.44 | 1628.00% | 1180.00% | 6982.00% | -13.57% | -0.84 | -51.94% | 0.00% | 0.00% | 0.00% | -0.61 | -0.83 | 0.24 | 1.46 |
| SENS | Senseonics Holdings, Inc. | $8.27 | 337.9M | +200% | +728% | — | — | -5.18 | -24.61 | 18.13 | -5.73 | -38.01 | -23.91 | 2.37% | -333.05% | -349.84% | -817.17% | 267.39% | -65.88% | -3.69 | -8.87 | 2.35 | 2.13 | 0.20 | 1364.00% | 37.00% | -1107.00% | -15.39% | -1.56 | 224.02% | 0.00% | 0.00% | 0.00% | -5.26 | -6.28 | 17.53 | -12.73 |
| SGHT | Sight Sciences, Inc. | $5.16 | 272.82M | +483% | -76% | — | — | -2.30 | 1.35 | 1.48 | -0.83 | — | 1.35 | 85.50% | -63.27% | -64.49% | -49.59% | -403.80% | -33.29% | 0.46 | -10.84 | 9.04 | 8.48 | 1.74 | -965.00% | -147.00% | -5261.00% | -19.22% | -1.44 | -181.68% | 0.00% | 0.00% | 0.00% | -0.76 | -1.69 | 0.48 | -1.67 |
| SNWV | SANUWAVE Health, Inc. | $24.33 | 208.62M | +2,106% | +2,696% | — | — | -4.13 | -10.18 | 3.97 | -8.74 | — | -5.46 | 75.23% | 16.60% | -96.13% | 112.25% | -90.44% | -119.43% | -2.00 | 0.40 | 0.43 | 0.32 | -0.92 | -4233.00% | 5999.00% | -14330.00% | 1.52% | 0.06 | -32.81% | 0.00% | 0.00% | 10.35% | 26.71 | 73.63 | 4.43 | -9.15 |
About 908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- CEO
- Kevin J. Knopp
- Employees
- 246
- Beta
- 0.49
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.10 ÷ $6.81) − 1 = -83.85% (DCF, example).